![David Sourdive](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Sourdive
Fondateur chez
CELLECTIS S.A.
Fortune : 3 M $ au 31/07/2026
Profil
David J.
Sourdive is the founder of Genepred Biotechnologies SAS, founded in 2012, and Cellectis SA, founded in 1999, where the title held is Director & Executive VP-CMC & Manufacturing.
Current jobs include Chairman at Mablink Bioscience SAS, Director at Exeliom Biosciences, Director at Cell-Easy SAS since 2021, and Venture Partner at Elaia Partners SAS since 2019.
Former jobs include Chairman & Chief Executive Officer at Takara Bio Europe AB, President & Chief Executive Officer at Ectycell SASU from 2009 to 2012, Director at Medicen Paris Region, Director at Cellectis AB, Director at Département de la Seine-Saint-Denis (France), Director at Mediterranean Institute For Life Sciences, Director at EnobraQ SAS from 2018 to 2021, Director at Eukarys SAS from 2015 to 2019, and Director at Omics SAS from 2017 to 2020.
Education includes undergraduate studies at Ecole Polytechnique.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CELLECTIS S.A. 1,38 % | 15/02/2026 | 997 725 ( 1,38 % ) | 3 M $ | 31/07/2026 |
Postes actifs de David Sourdive
| Sociétés | Poste | Début |
|---|---|---|
| CELLECTIS S.A. | Fondateur | 20/12/1999 |
Elaia Partners SAS
 Elaia Partners SAS Investment ManagersFinance Elaia is an active, long-term manager which invests in software technology companies, primarily in France and on a case by case basis in other European countries. The firm typically invests €1-€2 million, alone or through syndicated rounds, allocating additional financing to the future financing needs of the investee company. Elaia's investment strategy aims to maximize diversification within software-related technologies. They seek to create a balanced portfolio allocation based on four diversification criteria: development stage, geographical location, economic model and market segment. The firm invests in companies in all development stages, with an emphasis on first rounds of venture capital and the ability to participate in special situations. This multi-stage approach generates a broad range of risk/reward profiles and different exit perspectives. They diversify by sector and economic model to address the widest range of opportunities within the software-related field. By diversifying geographically, they aim to allocate approximately 20% of their portfolio to European opportunities outside France, to provide better access to an international network and enlarge their understanding of the markets. Elaia participates as lead investor or as a follower in a syndicate, typically seeking a board position to accompany the management team through the key stages of the investee company's development, aiming to add value to the company. The firm seeks to invest in innovative, well-managed, high-growth companies in large, appealing markets, which meet customer's needs, ideally have an existing customer base, a realistic and sustainable business model and reasonable company valuation. | Private Equity Investor | 18/12/2019 |
Cell-Easy SAS
 Cell-Easy SAS Miscellaneous Commercial ServicesCommercial Services Operates as a stem cell contract development and manufacturing organization | Directeur/Membre du Conseil | 01/02/2021 |
Mablink Bioscience
 Mablink Bioscience Pharmaceuticals: MajorHealth Technology Manufactures antibody-drug conjugates | Président | - |
Exeliom Biosciences
 Exeliom Biosciences BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company, which develops probiotics | Directeur/Membre du Conseil | - |
Anciens postes connus de David Sourdive
| Sociétés | Poste | Fin |
|---|---|---|
EnobraQ SAS
 EnobraQ SAS Chemicals: Major DiversifiedProcess Industries Develops yeast for the production of chemical compounds | Directeur/Membre du Conseil | 01/12/2021 |
Omics SAS
 Omics SAS Founded in 2024, Omics SAS is a French biotechnology company focused on developing foundation AI models for biology, with an emphasis on plant biology. The company is based in Paris, France. The company's flagship product, Botanic, is a family of AI models for plant genomics, beginning with Botanic-0—a model with 1 billion parameters trained on over 1,600 curated plant genomes. Botanic-0 predicts gene functions, regulatory elements, and trait associations, aiming to accelerate the crop trait discovery process. | Directeur/Membre du Conseil | 01/05/2020 |
Eukarys SAS | Directeur/Membre du Conseil | 01/12/2019 |
Ectycell SASU
 Ectycell SASU BiotechnologyHealth Technology Produces and sales stem cells | Directeur Général | 01/01/2012 |
| ░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de David Sourdive
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
62
Relations au 1er degré
16
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 16 |
|---|---|
Cellectis SA
 Cellectis SA Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops immunotherapies | Health Technology |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia is an active, long-term manager which invests in software technology companies, primarily in France and on a case by case basis in other European countries. The firm typically invests €1-€2 million, alone or through syndicated rounds, allocating additional financing to the future financing needs of the investee company. Elaia's investment strategy aims to maximize diversification within software-related technologies. They seek to create a balanced portfolio allocation based on four diversification criteria: development stage, geographical location, economic model and market segment. The firm invests in companies in all development stages, with an emphasis on first rounds of venture capital and the ability to participate in special situations. This multi-stage approach generates a broad range of risk/reward profiles and different exit perspectives. They diversify by sector and economic model to address the widest range of opportunities within the software-related field. By diversifying geographically, they aim to allocate approximately 20% of their portfolio to European opportunities outside France, to provide better access to an international network and enlarge their understanding of the markets. Elaia participates as lead investor or as a follower in a syndicate, typically seeking a board position to accompany the management team through the key stages of the investee company's development, aiming to add value to the company. The firm seeks to invest in innovative, well-managed, high-growth companies in large, appealing markets, which meet customer's needs, ideally have an existing customer base, a realistic and sustainable business model and reasonable company valuation. | Finance |
Ecole Polytechnique
 Ecole Polytechnique Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Takara Bio Europe AB
 Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Develops hepatocytes and cardiomyocytes from the proprietary stem cells | Commercial Services |
Ectycell SASU
Ectycell SASU BiotechnologyHealth Technology Produces and sales stem cells | Health Technology |
Medicen Paris Region
 Medicen Paris Region Hospital/Nursing ManagementHealth Services Operates as diagnostic and therapeutic firm | Health Services |
Cellectis AB
 Cellectis AB BiotechnologyHealth Technology Manufactures and distributes stem cell-related products | Health Technology |
Département de la Seine-Saint-Denis (France)
 Département de la Seine-Saint-Denis (France) Province/StateGovernment Functions as a local level government authority | Government |
Mediterranean Institute For Life Sciences | |
Bilhi Genetics SAS
 Bilhi Genetics SAS Pharmaceuticals: OtherHealth Technology Specializes in the development of predictive medicines | Health Technology |
EnobraQ SAS
EnobraQ SAS Chemicals: Major DiversifiedProcess Industries Develops yeast for the production of chemical compounds | Process Industries |
Eukarys SAS | |
Exeliom Biosciences
Exeliom Biosciences BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company, which develops probiotics | Health Technology |
Cell-Easy SAS
Cell-Easy SAS Miscellaneous Commercial ServicesCommercial Services Operates as a stem cell contract development and manufacturing organization | Commercial Services |
Omics SAS
Omics SAS Founded in 2024, Omics SAS is a French biotechnology company focused on developing foundation AI models for biology, with an emphasis on plant biology. The company is based in Paris, France. The company's flagship product, Botanic, is a family of AI models for plant genomics, beginning with Botanic-0—a model with 1 billion parameters trained on over 1,600 curated plant genomes. Botanic-0 predicts gene functions, regulatory elements, and trait associations, aiming to accelerate the crop trait discovery process. | |
Mablink Bioscience
Mablink Bioscience Pharmaceuticals: MajorHealth Technology Manufactures antibody-drug conjugates | Health Technology |
